A Panel Of MicroRNA Signature In Serum For Prostate Cancer Diagnosis

Purpose.Micro RNAs(miRNAs)could be stably preserved and detected in serum or plasma and could act as biomarkers in cancer diagnosis.Prostate cancer(PC)is the most frequently diagnosed cancer in men and the second leading cause of male cancer mortality.This study aimed to establish a circulating serum miRNA panel as a noninvasive biomarker for PC.Methods.The miRNA expression levels of 86 PC patients and 86 normal controls(NCs)in serum were detected by quantitative real-time polymerase chain reaction(q RT-PCR)through a four-stage experimental process.We constructed a logistic regression model based on candidate miRNAs’ expression profile to establish an ideal diagnostic miRNA combination.Receiver operating characteristic curves(ROC)were made to evaluate the diagnostic accuracy.We also compared the diagnostic value of the 3-miRNA panel with previously reported biomarkers and verified them in four public datasets.Also,to explore the potential existence of the identified miRNAs,we detected miRNA expressions in tissue and the matched adjacent normal tissue samples and exosome samples.Results.We identified a miRNA signature of three up-regulated miRNAs(miR-146a-5p,miR-24-3p,and miR-93-5p).Areas under the receiver operating characteristic curve(AUC)of the three-miRNA panel for the training,testing,and external validation phase were 0.819,0.831,and 0.814,respectively.The diagnostic performance of the identified 3-miRNA signature shows stability in the large cohorts of the four public datasets and superior to previously identified miRNA biomarkers.What’s more,the expression level of miR-93-5p was also elevated in exosomes in PC samples.However,in PC tissue samples,none of the three miRNAs showed significantly dysregulated expression.Conclusions.We established a three-miRNA panel(miR-146a-5p,miR-24-3p,and miR-93-5p)which could act as a non-invasive serum biomarker to diagnose PC.